IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC

Cellular Physiology and Biochemistry

Volumn 34, Issue 5, 2014, Pages 1578-1588

  Tian, Zhennan ^a   Yao, Guodong ^a   Song, Hongtao ^a   Zhou, Yang ^a   Geng, Jingshu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; IGF 2 receptor; Non small cell lung cancer; Prognosis

Indexed keywords

CISPLATIN; SMALL INTERFERING RNA; SOMATOMEDIN B RECEPTOR;

A549 CELL LINE; ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CALU 3 CELL LINE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; H292 CELL LINE; HUMAN; IC50; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; NCI H23 CELL LINE; NCI H460 CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SMOKING; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, IGF TYPE 2; RNA, SMALL INTERFERING;

EID: 84911474551     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366361     Document Type: Article

References (31)

1. Kocaturk CI, Gunluoglu MZ, Cansever L, Dincer IS, Bedirhan MA: Prognosis in patients with non-small cell lung cancer and satellite tumors. Thorac Cardiovasc Surg 2011;59:360-363.
2. Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL: Survival rates and tolerability of platinumbased chemotherapy regimens for elderly patients with non-small-cell lung cancer (nsclc). Lung Cancer 2006;53:171-176.
3. Chang CH, Chen KY, Young-Xu Y, Kurth T, Orav EJ, Yang PC, Chan KA: The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in east asia: A meta-analysis. Lung Cancer 2008;62:242-252.
4. Hotta K, Kiura K: Role of platinum-based radio-chemotherapy for locally advanced non-small-cell lung cancer: Possible influence of type of platinum on survival data. Ann Oncol 2006;17:1724.
5. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, Yu IR, Luketich JD: Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2007;133:352-363.
6. Han M, Liu Q, Yu J, Zheng S: Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer. Clin Chem Lab Med 2010;48:863-867.
7. Dziadziuszko R, Camidge DR, Hirsch FR: The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008;3:815-818.
8. Velcheti V, Govindan R: Insulin-like growth factor and lung cancer. J Thorac Oncol 2006;1:607-610.
9. Schairer C, McCarty CA, Isaacs C, Sue LY, Pollak MN, Berg CD, Ziegler RG: Circulating insulin-like growth factor (igf)-i and igf binding protein (igfbp)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (plco) cohort. Horm Cancer 2010;1:100-111.
10. Weroha SJ, Haluska P: The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012;41:335-350, vi.
11. Pollak M: The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012;18:40-50.
12. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ: The mannose 6-phosphate/insulin-like growth factor 2 receptor (m6p/igf2r), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-281.
13. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL: M6p/igf2r is mutated in squamous cell carcinoma of the lung. Oncogene 2000;19:1572-1578.
14. Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, Karasmanis I, Leva S, Angouridakis N, Vlachtsis K, Nikolaou A, Konstantinidis I, Fountzilas G: Insulin-like growth factor 1 receptor (igf1r) expression and survival in operable squamous-cell laryngeal cancer. PLoS One 2013;8:e54048.
15. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR: Insulin-like growth factor-1 receptor (igf-1r) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr) 2013;36:277-288.
16. Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, Feng X: Rage genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced nsclc. PLoS One 2012;7:e43734.
17. El-Shewy HM, Lee MH, Obeid LM, Jaffa AA, Luttrell LM: The insulin-like growth factor type 1 and insulinlike growth factor type 2/mannose-6-phosphate receptors independently regulate erk1/2 activity in hek293 cells. J Biol Chem 2007;282:26150-26157.
18. Harris LK, Crocker IP, Baker PN, Aplin JD, Westwood M: Igf2 actions on trophoblast in human placenta are regulated by the insulin-like growth factor 2 receptor, which can function as both a signaling and clearance receptor. Biol Reprod 2011;84:440-446.
19. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 2000;92:1472-1489.
20. Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, Lin X, Magaye R, Zhao J: Expression and clinical significance of igf-1, igfbp-3, and igfbp-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. OncoTargets and therapy 2013;6:1437-1444.
21. Souza RF, Wang S, Thakar M, Smolinski KN, Yin J, Zou TT, Kong D, Abraham JM, Toretsky JA, Meltzer SJ: Expression of the wild-type insulin-like growth factor ii receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999;18:4063-4068.
22. Zhang ZF, Pei BX, Wang AL, Zhang LM, Sun BS, Jiang RC, Wang CL: Expressions of cldn1 and insulin-like growth factor 2 are associated with poor prognosis in stage n2 non-small cell lung cancer. Chinese medical journal 2013;126:3668-3674.
23. Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N: Serum osteopontin, but not opn gene polymorphism, is associated with lvh in essential hypertensive patients. J Mol Med (Berl) 2014;92:487-495.
24. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colonystimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.
25. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, Kim T, Lee TJ, Jeon YJ, Nuovo GJ, Volinia S, He Q, Yu J, Nana-Sinkam P, Croce CM: Insulin growth factor signaling is regulated by microrna-486, an underexpressed microrna in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2013;110:15043-15048.
26. Yi L, Hou X, Zhou J, Xu L, Ouyang Q, Liang H, Zheng Z, Chen H, Xu M: Hif-1alpha genetic variants and protein expression confer the susceptibility and prognosis of gliomas. Neuromolecular Med 2014;16:578-586.
27. Ghosh P, Dahms NM, Kornfeld S: Mannose 6-phosphate receptors: New twists in the tale. Nature reviews Molecular cell biology 2003;4:202-212.
28. Kotsinas A, Evangelou K, Sideridou M, Kotzamanis G, Constantinides C, Zavras AI, Douglass CW, Papavassiliou AG, Gorgoulis VG: The 3' utr igf2r-a2/b2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. Cancer letters 2008;259:177-185.
29. Jing M, Li B, Hou X, Shoba J, Li C, Liang H, Zhang X, Liu E, Yang B, Meng X: Opn gene polymorphism and the serum opn levels confer the susceptibility and prognosis of ischemic stroke in chinese patients. Cell Physiol Biochem 2013;32:1798-1807.
30. Kim TR, Cho EW, Paik SG, Kim IG: Hypoxia-induced sm22alpha in a549 cells activates the igf1r/pi3k/akt pathway, conferring cellular resistance against chemo- and radiation therapy. FEBS letters 2012;586:303-309.
31. Hou X, Hu Z, Xu H, Xu J, Zhang S, Zhong Y, He X, Wang N: Advanced glycation endproducts trigger autophagy in cadiomyocyte via rage/pi3k/akt/mtor pathway. Cardiovasc Diabetol 2014;13:78.